TRENTON, NJ (April 13, 2018) – BioNJ’s Eighth Annual BioPartnering Conference, scheduled for Thursday, May 3, 2018 at The Palace at Somerset Park, Somerset, will bring together nearly 400 life sciences professionals from the Northeast to Mid-Atlantic states for a day of networking, 1:1 partnering meetings, company presentations, posters, exhibits and plenary sessions.
“We’re thrilled to be partnering once again with J.P. Morgan on BioNJ’s BioPartnering Conference, entitled The Evolving Marketplace New World Order: Implications on Partnering & Deal Making” said Debbie Hart, President and CEO, BioNJ. “The robust full-day syllabus is designed to foster productive partnerships, create fruitful opportunities, grow the ecosystem and bolster medical innovation. We have companies attending from 12 states — and the list is growing every day.”
Hear from industry experts on capital strategy, investor perspectives, M&A and industry trends and expectations:
Dominic Caruso, Executive Vice President and Chief Financial Officer, Johnson & Johnson
Michael Griffin, Managing Director, Investment Specialist, J.P. Morgan
Matthew Roden, Ph.D., Head of Strategic Corporate Development & Global BD Assessment, Bristol-Myers Squibb
Nimish Shah, VHCP, Investment Professional, Venrock
Nishit Trivedi, Ph.D., Director, Life Sciences and Vice President, Corporate Strategy & Development, Emerald Asset Management
Stephen Van Besien, Managing Director, Private Bank, J.P. Morgan
John Whittaker, Executive Director Healthcare Investment Banking, J.P. Morgan
Jerome Zeldis, M.D., Ph.D., CMO and President, Clinical Research, Medical Affairs and Regulatory Sorrento Therapeutics
Discuss research collaborations with world-renowned regional institutions:
Coriell Institute for Medical Research
Hackensack Meridian Health
New Jersey Institute of Technology
New York University
Rutgers, The State University of New Jersey
Tufts Medical Center
University of Pennsylvania
The Wistar Institute
Hear from Presenting Companies on their emerging technologies:
Aclipse Therapeutics, LLC
Acutive Technologies, Inc.
Apexian Pharmaceuticals Company
Azure Biotech, Inc.
AzurRx BioPharma, Inc.
BioAegis Therapeutics, Inc.
Cancer Genetics, Inc.
Citius Pharmaceuticals, Inc.
ContraVir Pharmaceuticals, Inc.
Engage Therapeutics, Inc.
Hemispherx BioPharma, Inc.
Matinas BioPharma Holdings, Inc.
OncoSec Medical, Inc.
Rafael Pharmaceuticals, Inc.
Skyran Biologics, Inc.
Thank you to our Sponsors and Supporting Partners Amicus Therapeutics; Ashton Tweed; BIO; BioCT; Brand Institute; Bristol-Myers Squibb; Choose New Jersey; Delaware Bio; Dynamic Strategies; EisnerAmper; Fisher Scientific; FlexPro Group; Friedman LLP; Haug Partners; Invest in Ontario; Johnson & Johnson; Lab Owl; Licensing Executive Society; MassBio; Masy BioServices; McCarter & English; Merck & Co.; Merrill Corporation; New Jersey Economic Development Authority; New Jersey Health Foundation; New York BIO; Pfizer; Precision Medicine Leaders Summit; Princeton Innovation Center; RSM; RxS; Withum.
BioNJ is a trade association of nearly 400 Member companies representing research-based life sciences organizations and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t Wait®, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org.
Vice President, Communications and Marketing